Wiley Blackwell

SHERPA: Unknown

People

  1. Horwitz
    Horwitz
  2. Yahalom
    Yahalom
  3. Palomba
    Palomba
  4. Salles
    Salles
  5. Moskowitz
    Moskowitz
  6. Zelenetz
    Zelenetz
  7. Kumar
    Kumar
  8. Noy
    Noy
  9. Hamlin
    Hamlin
  10. Imber
    Imber

Groups

  1. Hematologic Malignancies, Division of (170)
  2. Department of Medicine (167)
  3. Center for Hematologic Malignancies (134)
  4. Lymphoma (110)
  5. Survivorship Research (55)
  6. Population Sciences Research Program (38)
  7. Radiation Oncology, Department of (35)
  8. Sloan Kettering Institute Postdocs (31)
  9. Executive Committee, Center for Hematologic Malignancies (26)
  10. Epidemiology and Biostatistics (24)
Search Within
  1. "Hematological Oncology"
Formats
  1. Meeting Abstract (175)
  2. Journal Article (12)
  3. Review (5)
  4. Conference Paper (4)
  5. Research Letter (2)
Groups
  1. Hematologic Malignancies, Division of (170)
  2. Department of Medicine (167)
  3. Center for Hematologic Malignancies (134)
  4. Lymphoma (110)
  5. Survivorship Research (55)
  6. Population Sciences Research Program (38)

More Groups

People
  1. Steven Horwitz (38)
  2. Joachim Yahalom (34)
  3. Maria Palomba (30)
  4. Gilles Salles (28)
  5. Alison Moskowitz (23)
  6. Anas Younes (22)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (66)
  4. 2022 (3)
  5. 2021 (32)
  6. 2020 (2)

More Years

Publications
  1. Hematological Oncology (198)

Results (198)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characteristics of patients achieving complete or partial response (CR/PR) with tazemetostat (TAZ) in wild‐type relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Salles, G.; Tilly, H.; Chaidos, A.; McKay, P.; Phillips, T.; Assouline, S.; Campbell, P.; Ribrag, V.; Laurent Damaj, G.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Estimation of long‐term survival with tafasitamab + lenalidomide (LEN) in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Salles, G.; Goswami, B.; Bagnardi, V.; Dey, D.; Winderlich, M.; Ambarkhane, S.; Huang, D.; Nowakowski, G. S.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • First‐in‐human study of the EZH1 and EZH2 dual inhibitor valemetostat tosylate (DS‐3201b) in patients with relapsed or refractory non‐Hodgkin lymphomas
    Meeting Abstract

    Ishitsuka, K.; Izutsu, K.; Maruyama, D.; Makita, S.; Jacobsen, E. D.; Horwitz, S.; Kusumoto, S.; Allen, P.; Porcu, P.; Imaizumi, Y.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Cardiotoxicity risk in patients with non‐Hodgkin lymphoma receiving epoch after prior anthracycline exposure
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Matasar, M. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Time to second line Bruton tyrosine kinase therapy and age at its initiation are strongly associated with subsequent overall survival in patients with first relapse of mantle cell lymphoma
    Meeting Abstract

    Villa, D.; Jiang, A.; Crosbie, N.; Rule, S.; McCulloch, R.; Visco, C.; Buege, M. J.; Kumar, A.; Bond, D.; Paludo, J.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Zandelisib, a PI3Kδ inhibitor on intermittent schedule (IS) in follicular lymphoma patients who progressed within 24 months of first‐line chemoimunotherapy (POD24)
    Meeting Abstract

    Pagel, J.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H.; Kenkre, V. P.; Soumerai, J. D.; Llorin‐Sangalang, J.; Gorbatchevsky, I.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Prognostic significance of time from last therapy in patients with diffuse large B‐cell lymphoma: Retrospective analysis of electronic health records and claims data in the US
    Meeting Abstract

    Matasar, M.; Castro, F.; Liu, Y.; Abraham, A.; Oki, Y.; Dickinson, M.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save